87776-75-8

Basic information

• Product Name: 3-Chloro-4-(methylthio)phenylacetic acid
• Synonyms: 3-Chloro-4-(methylthio)phenylacetic acid;3-CHLORO-4-(METHYLTHIO)PHENYLACETIC;3-Chloro-4-(methylth
• CAS NO: 87776-75-8
• Molecular Formula: C₉H₉ClO₂S
• Molecular Weight: 216.68
• Mol File: 87776-75-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 351.233°C at 760 mmHg
• Flash Point: 166.22°C
• Appearance: /
• Density: 1.364g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.611
• PKA: 4.17±0.10(Predicted)
• CAS DataBase Reference: 3-Chloro-4-(methylthio)phenylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-4-(methylthio)phenylacetic acid(87776-75-8)
• EPA Substance Registry System: 3-Chloro-4-(methylthio)phenylacetic acid(87776-75-8)

Safety Data

• Hazardous Substances Data: 87776-75-8(Hazardous Substances Data)

Usage

General Description

3-Chloro-4-(methylthio)phenylacetic acid is a chemical compound with the molecular formula C9H9ClO2S. It is an organic compound with a chloro-substituted aromatic ring and a carboxylic acid group. The presence of a methylthio group in the molecule makes it a thioether. 3-Chloro-4-(methylthio)phenylacetic acid is often used as a biochemical research reagent and an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has important applications in the fields of organic chemistry, medicinal chemistry, and biotechnology, making it a valuable chemical in various industries and research activities.

InChI:InChI=1/C9H9ClO2S/c1-13-8-3-2-6(4-7(8)10)5-9(11)12/h2-4H,5H2,1H3,(H,11,12)

Upstream product

• 300355-11-7 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid ethyl ester 
• 393165-02-1 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester 
• 17733-22-1 2-chlorothioanisole 
• 947701-13-5 3-chloro-4-methylthio-phenylacetonitrile 
• 947701-14-6 3-chloro-4-methylthiophenylacetic thiomorpholide 

Downstream Products

• 436141-65-0 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid methyl ester 
• 1072429-71-0 2-(3-chloro-4-(methylthio)phenyl)propanoic acid 
• 588940-69-6 (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide 
• 1393926-51-6 2(R)-(3-chloro-4-methylsulfanylphenyl)-N-methyl-N-[1(R)-methyl-2-oxo-2(R)-phenylethyl]-3-(2-oxocyclopentyl)proprionamide 
• 625113-52-2 (2R)-2-(3-chloro-4-methanesulfonylphenyl)-3-(2-oxocyclopentyl)propanoic acid 
• 625114-41-2 Piragliatin 
• 625114-00-3 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-(3-formyloxy-cyclopentyl)propionic acid 
• 625114-43-4 (2R)-2-(3-chloro-4-methanesulfonylphenyl)-3-[(1R)-3-oxocyclopentyl]propanoic acid 
• 588940-74-3 (2R)-2-[3-chloro-4-(methylsulfanyl)phenyl]-3-cyclopentyl-N-[(1R,2R)-1-hydroxy-1-phenylpropan-2-yl]-N-methylpropanamide 
• 588940-80-1 (2R)-2-[3-chloro-4-(methylsulfanyl)phenyl]-3-cyclopentylpropanoic acid 
• 588941-45-1 RO 0505082 

Relevant articles and documents

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN SO2-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a S02-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions

Vanilloid receptor ligand compounds corresponding to formula I: a process for producing such compounds, pharmaceutical compositions containing them, and the use of such compounds to treat pain and various other vanilloid receptor mediated conditions.

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.